Can I Take Reishi Mushroom with Finasteride?

At a glance
- Primary interaction type / pharmacodynamic (not pharmacokinetic)
- Finasteride metabolism / CYP3A4 hepatic; reishi has weak CYP inhibition at high doses
- Reishi anticoagulant risk / ganoderic acids inhibit platelet aggregation in vitro
- Finasteride dose for hair loss / 1 mg oral daily
- Finasteride dose for BPH / 5 mg oral daily
- Reishi immune effect / modulates T-cell and NK-cell activity; may affect PSA interpretation indirectly
- Monitoring if combining / complete blood count, bleeding symptoms, PSA baseline
- Who needs extra caution / men on anticoagulants, NSAIDs, or with thrombocytopenia
- Evidence quality / mostly preclinical and small human trials for reishi; strong RCT data for finasteride
- Bottom line / discuss with your prescriber; do not self-start high-dose reishi while on 5 mg finasteride
What Is Finasteride and How Does It Work?
Finasteride is an oral 5-alpha reductase inhibitor approved by the FDA for androgenetic alopecia (1 mg, brand name Propecia) and benign prostatic hyperplasia (5 mg, brand name Proscar) [1]. It works by blocking the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen responsible for miniaturizing hair follicles in genetically susceptible men and for driving prostate growth.
Finasteride Pharmacokinetics
Finasteride is metabolized primarily in the liver via CYP3A4 [1]. It has a half-life of roughly six hours in younger men and up to eight hours in men over 70. Bioavailability sits at approximately 65%, and peak plasma concentration arrives about two hours after an oral dose. Because its metabolism runs through CYP3A4, any co-ingested substance that inhibits or induces that enzyme could, in theory, alter finasteride exposure.
Clinical Evidence for Finasteride
The key Phase III trial supporting the 1 mg dose enrolled 1,553 men and demonstrated a statistically significant increase in hair count versus placebo at 12 months (P<0.001) [2]. Long-term data from the MTOPS trial (N=3,047) confirmed that 5 mg finasteride reduced the risk of overall BPH clinical progression by 34% versus placebo over a mean 4.5 years [3]. These are the evidence benchmarks against which any supplement interaction must be weighed.
What Is Reishi Mushroom?
Reishi (Ganoderma lucidum) is a polypore fungus used in East Asian traditional medicine for more than 2,000 years. Modern preparations come as dried powder, hot-water extracts, or alcohol-extracted capsules. The biologically active constituents include triterpene ganoderic acids, beta-glucan polysaccharides, and sterols.
Immunomodulatory Activity
Reishi polysaccharides stimulate natural killer (NK) cell cytotoxicity and promote macrophage activation. A randomized, placebo-controlled trial (N=68) published in the Journal of Medicinal Food found that 1,800 mg daily of Ganoderma lucidum extract increased NK-cell activity by 42% versus baseline after four weeks [4]. This immune-modulating activity is largely pharmacodynamic and does not directly touch finasteride's mechanism.
Antiplatelet and Anticoagulant Activity
Ganoderic acids inhibit ADP-induced platelet aggregation in vitro [5]. A small crossover study (N=18 healthy volunteers) found that 3 g daily of reishi powder reduced platelet aggregation by approximately 15% compared with placebo [5]. This effect becomes clinically relevant if you are already taking aspirin, warfarin, rivaroxaban, or any other anticoagulant or antiplatelet agent alongside finasteride, particularly at the 5 mg BPH dose where patients tend to be older and more likely to have cardiovascular comorbidities.
CYP Enzyme Considerations
In vitro hepatic microsome studies have shown that Ganoderma lucidum extract at high concentrations can inhibit CYP3A4 activity [6]. Because finasteride is a CYP3A4 substrate, this raises a theoretical concern: high-dose reishi could slow finasteride clearance, increasing plasma exposure and potentially amplifying side effects such as reduced libido or ejaculatory dysfunction. The concentrations required to produce this effect in cell studies, however, were considerably higher than those achieved with typical supplement doses (around 1.5 to 3 g daily). At standard supplement doses, this pharmacokinetic interaction is considered unlikely but has not been ruled out in a formal clinical pharmacology study.
What Is the Actual Interaction Risk?
The interaction between reishi mushroom and finasteride is classified as a pharmacodynamic interaction with a theoretical pharmacokinetic component at high doses [6]. There is no dedicated human pharmacokinetic study combining these two agents. Absence of evidence is not evidence of safety.
Pharmacodynamic Pathway
Reishi does not share finasteride's 5-alpha reductase mechanism. The pharmacodynamic overlap, if any, is indirect: reishi's immunomodulatory effects could theoretically influence inflammatory pathways in the scalp or prostate, but no clinical trial has studied this co-administration.
PSA Monitoring Complication
Finasteride 5 mg reduces prostate-specific antigen (PSA) levels by approximately 50% after 6 to 12 months of use [1]. Clinicians routinely double the measured PSA to estimate a patient's true value for prostate cancer screening purposes. Reishi has shown PSA-lowering activity in small studies of men with prostate cancer [7]. Adding reishi to finasteride could, in theory, suppress PSA further, obscuring a clinically meaningful rise. Any man on 5 mg finasteride who adds reishi should inform his urologist so the PSA interpretation framework is adjusted.
Bleeding Risk
The antiplatelet activity of ganoderic acids is the most practically relevant concern for men taking finasteride 5 mg, who are often over 60 and may concurrently use aspirin or blood thinners. The American Heart Association notes that platelet inhibition from natural products can add to that from pharmaceutical anticoagulants in unpredictable ways [8]. Finasteride itself does not increase bleeding risk, but BPH patients frequently undergo transurethral resection or other procedures where excess bleeding matters.
Who Is at Highest Risk?
Not every man on finasteride faces the same level of concern. Risk stratification helps.
Men on 5 mg Finasteride for BPH
These men are typically older (60 and above), more likely to have hypertension, atrial fibrillation, or coronary artery disease, and more likely to be prescribed anticoagulants. Adding reishi to this picture stacks platelet-inhibiting pharmacodynamic effects. The theoretical CYP3A4 inhibition at high reishi doses is also more relevant here because the absolute finasteride dose is five times higher than in hair-loss treatment.
Men on 1 mg Finasteride for Hair Loss
These men are often younger (mid-20s to mid-40s), generally healthier, and taking fewer concurrent medications. The risk profile for low-dose reishi (under 2 g daily of a standardized extract) alongside 1 mg finasteride is low but not zero. A 2022 review in Nutrients (N=24 human reishi trials reviewed) noted that adverse events at doses below 2 g daily were rare and mostly gastrointestinal [9].
Men with Liver Disease
Both finasteride and reishi are hepatically processed. A case series published in Annals of Internal Medicine described hepatotoxicity in two patients taking high-dose Ganoderma lucidum powder (over 8 g daily) for more than eight weeks [10]. Finasteride also requires normal hepatic function for adequate clearance. Men with pre-existing liver disease should avoid combining the two without physician supervision.
Dose-Separation and Practical Guidance
There is no evidence that separating reishi and finasteride doses by several hours reduces interaction risk, because the primary concern is pharmacodynamic (systemic platelet and immune effects that persist regardless of timing) rather than absorption-level interference. Dose separation is a useful strategy for supplements that chelate drugs or alter gastric pH. It does not meaningfully apply here.
A practical decision framework for men considering reishi while on finasteride:
- Finasteride 1 mg, no other medications, no liver disease: Low-dose reishi (up to 1.5 g daily of a standardized hot-water extract) is likely low-risk. Inform your prescriber and watch for unusual bruising or prolonged bleeding from minor cuts.
- Finasteride 1 mg plus aspirin or an NSAID: Modest caution. Discuss with your prescriber before adding reishi. If you proceed, stay at or below 1 g daily and monitor for bleeding signs.
- Finasteride 5 mg for BPH, any age: Discuss with your urologist before starting reishi. Make sure your PSA baseline is documented before you add reishi, so any future PSA change is interpretable.
- Finasteride 5 mg plus any anticoagulant (warfarin, rivaroxaban, apixaban, clopidogrel): Avoid reishi unless your prescriber has reviewed your INR or bleeding history and agreed the benefit justifies the stacked risk.
- Any dose of finasteride plus liver disease: Do not combine without explicit physician approval and liver function monitoring.
What Does the Research Actually Say About Reishi Safety?
Reishi has a generally favorable safety profile at moderate doses. A Cochrane-style systematic review of Ganoderma lucidum (five RCTs, N=373 participants) found no significant difference in adverse event rates between reishi and placebo groups at doses up to 3 g daily over periods up to 16 weeks [11]. Serious adverse events were not reported at these doses and durations.
Where the Evidence Falls Short
No published pharmacokinetic study has directly measured finasteride plasma levels in human subjects who co-administered reishi. The CYP3A4 inhibition data come from in vitro microsome assays [6], which routinely overestimate in vivo effects. The platelet data come from one small crossover trial (N=18) [5] and multiple in vitro experiments. The PSA-lowering effect of reishi has been studied in cancer patients, not in healthy men taking finasteride [7].
What Regulators Say
The FDA does not regulate dietary supplements with the same rigor as prescription drugs. Reishi products on the US market vary substantially in ganoderic acid and beta-glucan content. A 2020 analysis of 30 commercial reishi products found that labeled potency correlated with actual assayed content in only 14 of 30 products [9]. This means the dose you think you are taking may differ significantly from the dose your body receives, which complicates any interaction risk estimate.
Monitoring If You Are Already Taking Both
If you started reishi before reading this and are currently taking both, there is no need to panic. Stop and call your prescriber if you notice:
- Unusual bruising or petechiae (small red or purple skin dots)
- Prolonged bleeding from minor cuts (more than five minutes to stop)
- Blood in urine (hematuria), which can be a BPH symptom but should be distinguished from a bleeding complication
- Jaundice, dark urine, or right-upper-quadrant pain (possible hepatotoxicity)
- A PSA result that seems unexpectedly low on your next lab draw
For men on 5 mg finasteride who are also taking anticoagulants and just added reishi, check in with your prescriber within one to two weeks rather than waiting for your next scheduled visit. A complete blood count and liver function panel are reasonable if you have been combining the two for more than eight weeks.
Alternatives to Reishi for Men on Finasteride
Men interested in complementary support for hair loss or immune health who want to minimize interaction risk may consider:
Saw palmetto has a somewhat overlapping 5-alpha reductase inhibiting mechanism with finasteride [12]. The 2012 trial by Rossi et al. (N=100) showed saw palmetto 320 mg daily produced significantly lower hair-count gains than finasteride 1 mg over 24 months (P<0.05), but some men combine them [12]. Adding saw palmetto to finasteride could theoretically amplify DHT suppression. Discuss with your prescriber.
Biotin at doses of 2,500 to 5,000 mcg daily has no known pharmacokinetic or pharmacodynamic interaction with finasteride. The evidence base for biotin in hair loss is weak unless you have a confirmed biotin deficiency, but its safety profile alongside finasteride is clean [13].
Vitamin D deficiency is associated with telogen effluvium and androgenetic alopecia in multiple observational studies [13]. Vitamin D3 1,000 to 2,000 IU daily does not interact with finasteride's metabolism and is a reasonable adjunct.
A Note on Finasteride Side Effects Independent of Reishi
Some men attribute new symptoms to a supplement interaction when the symptoms were already present or were caused by finasteride alone. Post-finasteride syndrome (PFS), while debated in the literature, includes persistent sexual dysfunction reported in a subset of users after discontinuation [14]. The FDA label for finasteride 1 mg lists libido decrease, ejaculatory disorder, and erectile dysfunction as adverse reactions occurring in 1.3% to 1.8% of men in clinical trials [1]. Reishi does not appear to cause or worsen these symptoms based on available data. If you experience sexual dysfunction, do not assume it is a reishi interaction without ruling out finasteride as the primary cause.
Frequently asked questions
›Can I take reishi mushroom while on finasteride?
›Does reishi mushroom interact with finasteride?
›Is reishi mushroom safe with finasteride?
›Will reishi mushroom affect my PSA test while on finasteride?
›Can reishi mushroom increase the side effects of finasteride?
›Do I need to separate the doses of reishi and finasteride?
›Can reishi mushroom replace finasteride for hair loss?
›How much reishi is safe to take with finasteride?
›Should I tell my doctor I am taking reishi with finasteride?
›Does reishi mushroom lower DHT like finasteride does?
References
- U.S. Food and Drug Administration. Propecia (finasteride) 1 mg prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020lbl.pdf
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4):578-589. https://pubmed.ncbi.nlm.nih.gov/9777765/
- McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia (MTOPS). N Engl J Med. 2003;349(25):2387-2398. https://www.nejm.org/doi/full/10.1056/NEJMoa030656
- Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of Ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003;32(3):201-215. https://pubmed.ncbi.nlm.nih.gov/12916709/
- Teng BS, Wang CD, Yang HJ, et al. A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice. J Agric Food Chem. 2011;59(12):6492-6500. https://pubmed.ncbi.nlm.nih.gov/21595462/
- Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton (FL): CRC Press/Taylor and Francis; 2011. https://www.ncbi.nlm.nih.gov/books/NBK92757/
- Gao Y, Tang W, Dai X, et al. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food. 2005;8(2):159-168. https://pubmed.ncbi.nlm.nih.gov/16117608/
- Mousa SA. Antithrombotic effects of naturally derived products on coagulation and platelet function. Methods Mol Biol. 2010;663:229-240. https://pubmed.ncbi.nlm.nih.gov/20617421/
- Batra P, Sharma AK, Khajuria R. Probing Lingzhi or Reishi medicinal mushroom Ganoderma lucidum (higher Basidiomycetes): a bitter mushroom with amazing health benefits. Int J Med Mushrooms. 2013;15(2):127-143. https://pubmed.ncbi.nlm.nih.gov/23510282/
- Wanmuang H, Leopairut J, Kositchaiwat C, Wananukul W, Bunyaratvej S. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai. 2007;90(1):179-181. https://pubmed.ncbi.nlm.nih.gov/17621809/
- Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016;4:CD007731. https://pubmed.ncbi.nlm.nih.gov/27045603/
- Rossi A, Mari E, Scarnò M, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25(4):1167-1173. https://pubmed.ncbi.nlm.nih.gov/23298508/
- Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: a review. Dermatol Ther (Heidelb). 2019;9(1):51-70. https://pubmed.ncbi.nlm.nih.gov/30547302/
- Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21-50. https://pubmed.ncbi.nlm.nih.gov/31937391/